Results 111 to 120 of about 2,835 (182)

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis. [PDF]

Nat Commun
Liu B, Spalinger MR, Invernizzi A, Gerdes E, Steglich B, Schwarzfischer M, Machicote A, Pelczar P, Pöhlmann D, Nawrocki M, Böttcher M, Aleko A, Velasquez LN, Wende S, Stallbaum F, Neuendorff J, Grosshauser S, Muscate F, Douilhet G, Perez LG, Sabihi M, Möller K, Viehweger F, Sutter JP, Kilian C, Kumar Y, Fründt T, Sauter G, Rösch T, Gagliani N, Caflisch A, Scharl M, Huber S.   +32 more
europepmc   +1 more source

A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis. [PDF]

Crohns Colitis 360
Kumar A, Baxter J, Rimmer P, Noble B, Bower J, Makki MU, Hatta A, Chikhlia A, Cheesbrough J, Disney B, Muir J, Karova M, Butterworth J, Sagar N, Al-Talib I, Nahal J, Ali N, Sagar V, Varyani F, Smith S, Bourne S, Hsu YK, Eltahir A, de Silva S, Harvey P.   +24 more
europepmc   +1 more source

CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma. [PDF]

Front Genet
Zhang L, Wang B, Zhang M.
europepmc   +1 more source

Effect of JAK Inhibitors on Pain Management in Patients with Rheumatoid Arthritis: A Literature Review. [PDF]

J Clin Med
Kowalska A, Jawoszek A, Borkowska A, Chmielewski G, Jaśkiewicz Ł, Krajewska-Włodarczyk M.   +5 more
europepmc   +1 more source

Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis. [PDF]

Clin J Gastroenterol
Madarame A, Kanda R, Shimizu Y, Itoi T.
europepmc   +1 more source

JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose-Response Network Meta-Analysis of Efficacy and Safety. [PDF]

JGH Open
Qtaishat FA, AlKayyat A, Yasin JA, A Tamimi MA, Tarawneh J, AlDaher L, Abdallah S, Alghaniem MMA, Abunamoos A, Musa A, Ateiwi YA, Taha Y, Tamimi TA.   +12 more
europepmc   +1 more source

Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. [PDF]

RMD Open
Martinez-Molina C, Frade-Sosa B, Diaz-Torné C, Sanmarti R, Corominas H.   +4 more
europepmc   +1 more source

Effectiveness and retention of certolizumab pegol and JAK inhibitors in rheumatoid arthritis: a multicenter retrospective study stratified by rheumatoid factor status. [PDF]

Front Med (Lausanne)
Parra-Moreno M, Ladehesa-Pineda L, Calvo-Gutierrez J, Cepas-Guitérrez FJ, Moreno-Caño E, Robustillo-Villarino M, Zúñiga-Vera A, Plasencia-Rodríguez C, Martinez-Feito A, Costa-Moya E, Taverner-Torrent D, Sainz-Comas L, Díaz-Torné C, Ruiz-Esquide V, Rojas C, Martin-de la Sierra Lopez L, Jiménez-Rodríguez L, Velasco-Sánchez D, Faré-García R, Juan-Mas A, Moreno-García MS, Acosta-Alfaro AV, Muñoz-Fernández S, Martín-López M, Zas R, Godoy-Navarrete J, Añon-Oñate I, Ortiz-Márquez F, Mena-Vázquez N, Estrada P, Ortega-Castro R, Escudero-Contreras A, López-Medina C.   +32 more
europepmc   +1 more source

Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination? [PDF]

Rheumatol Adv Pract
Rabee H, Mahto A.
europepmc   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease. [PDF]

J Gastroenterol Hepatol
Ooi CJ, Ling KL, Limsrivilai J, Wei SC, Mak JWY, Kobayashi T, Dang LM, Leong RW, Lin H, Weng MT, Ong WC, Ahuja V, Aniwan S, Hokari R, Lee WJJ, Leow AH, Leung WK, Lim WC, Makharia G, Matsuoka K, Mustaffa N, Ng SC, Philip M, Pisespongsa P, Ali RAR, Ran ZH, Simadibrata M, Sollano J, Tan M, Viet HD, Wan Ibrahim NR, Wu KC, Ye BD, Hilmi I, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD).   +34 more
europepmc   +1 more source